[ Back to EurekAlert! ] Public release date: 2-Nov-2009
[ | E-mail Share Share ]

Contact: Amanda Jekowsky
ajekowsk@acc.org
202-375-6645
American College of Cardiology

ACC/AHA revised guidelines for the perioperative use of beta blockers to minimize cardiac risk

Beta blockers should be considered within context of patients' risk

Cardiac complications around the time of noncardiac surgery are relatively common and can be serious. The American College of Cardiology (ACC) and the American Heart Association (AHA) today release a Focused Update to the Practice Guidelines based on new clinical trial data that summarizes and sheds light on the risks and benefits of using beta blockers to reduce cardiac events during noncardiac surgeries, and provides specific recommendations about which patients will likely benefit and in which patients there is not enough evidence to recommend their use.

"Any surgery, particularly a high-risk procedure, is a stress on the heart, especially for those with underlying circulation problems or other cardiovascular risk factors," says Kirsten E. Fleischmann, M.D., M.P.H., chair of the 2009 writing group that reviewed the latest evidence on the perioperative use of beta blockers. "In general, the higher the risk from a cardiovascular standpoint, the more likely a patient will benefit from beta blockers. However, newer data from the POISE [Perioperative Ischemic Evaluation] trial suggest that starting higher doses of beta blockers acutely on the day of surgery is associated with risk as well, so careful patient selection, dose adjustment and monitoring throughout the perioperative period is key."

More than 30 million noncardiac surgeries are performed in the United States each year. Cardiac problems around the time of surgery are a major cause of complications and death in these patients, prolonging hospitalizations and increasing costs. Beta blockers are designed to help protect against heart attack around the time of surgery by lowering heart rate and helping to block the effects of stress hormones on the heart.

The recommendation to continue beta blockers perioperatively in those patients who are already receiving them remains current since the initial 2007 guidelines were published. The workgroup advises beta blockers are reasonable to consider in:

However, authors caution that when beta blockers are started in patients not yet taking them, the medication should be initiated well before the procedure and titrated up as blood pressure and heart rate allow.

"We recommend beta blockers be started well in advance of surgery and not at higher doses right off the bat," says Dr. Fleischmann. "These updated guidelines are intended to provide guidance for the appropriate use of beta blockers to help reduce the risk of cardiac complications. Physicians must be vigilant in assessing patients' cardiac risk and weighing this against potential side effects of the therapy."

According to the authors, the usefulness of beta blockers remains uncertain in lower-risk patients or in those undergoing lower-risk surgeries (e.g., percutaneous or endovascular procedures), and requires careful consideration of the risks and benefits.

The guidelines do not advocate for routine administration of beta blockers, particularly in higher fixed-dose regimens, begun on the day of surgery based on data from the POISE study. While there was a reduction in perioperative myocardial infarction and primary cardiac events among study participants, the use of beta blockers was also associated with higher rates of stroke and overall mortality. Beta blockers should not be used when contraindications exist.

###

This ACCF/AHA update was developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, and Society for Vascular Surgery.

Full text of the Focused Update will be published in the November 24, 2009, issue of the Journal of the American College of Cardiology and the November 24, 2009, Circulation, and will be posted on the ACC (www.acc.org) and AHA (www.americanheart.org) Web sites.

Dr. Fleischmann reports no conflicts of interest.

The American College of Cardiology is leading the way to optimal cardiovascular care and disease prevention. The College is a 37,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care. More information about the association is available online at www.acc.org.

The American Heart Association, founded in 1924, is the nation's oldest and largest voluntary health organization dedicated to building healthier lives, free of heart disease and stroke. To help prevent, treat and defeat these diseases America's No. 1 and No. 3 killers we fund cutting-edge research, conduct lifesaving public and professional educational programs, and advocate to protect public health. To learn more or join us in helping all Americans, call 1-800-AHA-USA1 or visit americanheart.org.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.